• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
USM
Click for more information
0.65% $7.78

Smartshares US Mid Cap ETF Units - Charts / Financials

watchlist Created with Sketch. Add to my watchlist

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile arrow Created with Sketch.
See benefits
refresh Created with Sketch. REFRESH
Day
Open $7.73   Day High $7.78   Day Low $7.71
Daily Volume 46046
Bids   Sellers
Number Price Volume   Number Price Volume
0 $7.70 7   0 $7.80 1290

Data source: Refinitiv

(20min delay)
Last
$7.78 		Change
0.050(0.65%) 		Mkt cap ! n/a
Open High Low Value Volume
$7.73 $7.78 $7.71 $355.2K 46.04K

Buyers (Bids)

No. Vol. Price($)
0 7 $7.70
 

Sellers (Offers)

Price($) Vol. No.
$7.80 1290 0
Last trade - 11.15am 23/04/2024 (20 minute delay) ?

Top Stories

Tamboran steps on the gas to supply the Top End

Tamboran Resources has taken a significant step towards commercialising the gas resources of the Betaloo Sub Basin by signing a gas supply agreement with the Northern Territory Government.
Regal copper grades at Gascoyne play see shares jump 33% for Augustus Augustus Minerals is reporting high grade copper rock chip results at Ti-Tree in WA based on recent fieldwork.
Are there gains to be made with the grocery giants? There is a growing storm of controversy around Coles (ASX:COL) and Woolworths (ASX:WOW) as they face intense scrutiny over price hikes and supplier pressures in a Senate inquiry. This raises an interesting question as to whether investors should cut ties with these corporate giants or wheth...
AML3D secures Australian defence government contract AML3D signed a contract with the Australian Government Defence Science and Technology Group (DSTG) to supply components for marine defence
PharmAust CEO's sayanora triggers stock plunge Clinical-stage biotechnology company, PharmAust shares plunged 24 per cent so this morning, following the resignation of its CEO, Dr. Michael Thurn.
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.